Oncology drug development stands out as one of the most risky and potentially rewarding therapeutic areas

Currently, only 5% of Phase I oncology therapies make it to market, with an even smaller percentage being true commercial successes. Meanwhile, the global marketplace for oncology therapies is evolving rapidly, with unprecedented rapid growth and development in China and the rest of the Asia Pacific region.

In fact, Asia Pacific is now firmly at the forefront of modern oncology drug development. China is now the world’s second-largest pharmaceutical market. A recent white paper from Syneos Health® provides more insight on the reasons behind this shift and why adopting a global perspective on clinical trials is necessary to be successful in today’s increasingly competitive oncology environment.

Syneos Health

Share content on email